BRCA1 and breast carcinoma: They then used denosumab to the inhibit tumor necrosis factor superfamily member 11 (TNFSF11; also known as RANKL) signaling in breast cancer organoids derived from BRCA1 mutation tissue, effectively reducing tumor cell proliferation, identifying a targeted pathway in the primary cell population of BRCA1 mutation carriers, and proposing blocking RANKL as a promising breast cancer prevention strategy (59).